A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Fortrea Holdings Inc. FTRE

Weak broader-coverage candidate · Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices

On FrontierLab's discovery record since 2026-07-29 (3 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Weak" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-07-30), not the curated Frontier signal.

Key quality signals

Revenue growth (YoY)	-2.1%
Gross margin	17.1%
Gross profits / assets	0.17
Rule of 40	-1.7
Net margin	0.4%
Cash runway (months)	—
PEG	—
Price / sales	0.7

Quality checklist

✗ Revenue growth — -2.1% (pass ≥ 20%)
✗ Gross profits / assets — 0.17 (pass ≥ 0.33)
✗ Gross margin — 17.1% (pass ≥ 60%)
✓ Cash generation
~ Share dilution — 4.1%

Fundamentals — snapshot as of 2026-07-30

Stage	Established
Share issuance (YoY)	4.1% · modest issuance
Moat	—
TAM	—
P/E (trailing)	—
EPS (trailing)	$-0.93
Burn multiple	—
Gross-margin trend (pts)	-1.9
Cash / assets	0.06
Net debt / EBITDA	-1.1
Statements as of	Q2 FY2026 · filed 2026-07-29

Momentum context — a snapshot from 2026-07-30, not current

Price at surface	$20.40 (as of 2026-07-30)
52-week range	$5.265 – $21.39
% off 52-wk high	-4.6%
RSI (14)	72
Relative volume	2.3×

Risk flags

Thin gross margin — keeps little of each sales dollar (judge it against its industry).

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-07-30 (end-of-day). How grades are computed →